Development of inactivated cultural yellow fever vaccine
- Authors: Ivanov A.P.1, Klebleeva T.D.1, Rogova Y.V.1, Ivanova O.E.1,2
-
Affiliations:
- Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products, Russian Academy of Sciences
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
- Issue: Vol 65, No 4 (2020)
- Pages: 212-217
- Section: ORIGINAL RESEARCH
- URL: https://journals.rcsi.science/0507-4088/article/view/118134
- DOI: https://doi.org/10.36233/0507-4088-2020-65-4-212-217
- ID: 118134
Cite item
Full Text
Abstract
Introduction. The only currently available live vaccine against yellow fever (YF) based on chicken embryos infected with an attenuated 17D strain of the YF virus is one of the most effective vaccine preparations. However, the live vaccine is associated with “viscerotropic syndrome” (approximately 0.4 cases per 100 000 vaccinated). Therefore, the development and introduction of highly purified inactivated vaccine against YF is intended to ensure the maximum safety of vaccination against one of the most common human viral diseases.
Goals and objectives. Development and evaluation of immunogenicity of the cultural inactivated vaccine against YF at the laboratory model level.
Material and methods. Adaptation of 17D strain of YF virus to Vero cell culture, cultivation, removal of cellular DNA, inactivation with β-propiolactone, concentration, chromatographic purification, determination of protein and antigen of YF virus, assessment of immunogenicity in mice in parallel with commercial live vaccine.
Results and discussion. Immunogenicity: the determination of specific antibodies of class G (IgG) and virus neutralizing antibodies in the sera of immunized mice showed high level of antibodies exceeding that of immunized with commercial live vaccine. The optimal dose of antigen in the vaccine (total protein) was 50 μg/ml (5 μg/0.1 ml -dose and volume per 1 vaccination of mice). Thus, the laboratory version of cultural inactivated vaccine against YF is as effective (and even superior) as the commercial live vaccine.
Conclusion. Laboratory version of cultural inactivated vaccine against YF, which is not inferior in immunogenicity (in animal model) to commercial live vaccine, has been developed.
Full Text
##article.viewOnOriginalSite##About the authors
A. P. Ivanov
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products, Russian Academy of Sciences
Author for correspondence.
Email: ivanovalexander1@gmail.com
ORCID iD: 0000-0003-4576-7136
Alexander P. Ivanov – D. Sci. (Med.), leading researcher, laboratory of molecular biology of viruses.
Moscow, 108819
Russian FederationT. D. Klebleeva
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products, Russian Academy of Sciences
Email: fake@neicon.ru
ORCID iD: 0000-0003-4288-6818
Tatiana D. Klebleeva – junior researcher, laboratory of molecular biology of viruses.
Moscow, 108819
Russian FederationY. V. Rogova
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products, Russian Academy of Sciences
Email: fake@neicon.ru
ORCID iD: 0000-0002-4655-5330
Yulia V. Rogova - head of the department of experimental aAnimals.
Moscow, 108819 Russian FederationO. E. Ivanova
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products, Russian Academy of Sciences; I.M. Sechenov First Moscow State Medical University (Sechenov University)
Email: fake@neicon.ru
ORCID iD: 0000-0003-1784-4827
Ol'gaE. Ivanova - D. Sci. (Med.), leading researcher, laboratory of virology of poliomyelitis and other enterovirus infections with the WHO Polio Surveillance Center, Chumakov FSCRD of Immune-and-Biological Products of RAS; prof. of the Department of Organization and Technology of Immunobiological Preparations of the Institute of Translational Medicine and Biotechnology, Federal State Autonomous Educational Institution of Higher Education, I.M. Sechenov FMSMU.
Moscow, 11999, 108819 Russian FederationReferences
- Monath T.P., Lee C.K., Julander J.G., Brown A., Beasley D.W., Watts D.M., et al. Inactivated yellow fever 17D vaccine: Development and nonclinical safety, immunogenicity and protective activity. Vaccine. 2010; 28(22): 3827-40. DOI: http://doi.Org/10.1016/j.vaccine.2010.03.023
- Theiler M., Smith H.H. The use of yellow fever virus modified by in vitro cultivation for human immunization. J. Exp. Med. 1937; 65(6): 787-800. DOI: http://doi.org/10.1084/jem.65.6.787
- Yellow fever vaccine - current supply outlook. UNICEF Supply Division; 2016. Available at: https://www.unicef.org/supply/sites/unicef. org.supply/files/2019-06/yellow-fever-vaccine-supply-outlook.pdf
- Whittembury A., Ramirez G., Hernandes H., Ropero A.M., Waterman S., Ticona M., et al. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine. 2009; 27(43): 5974-81. DOI: http://doi.org/10.1016/j.vaccine.2009.07.082
- Hayes N.B. Is it time for a new yellow fever vaccine? Vaccine. 2010; 28(51): 8073-6. DOI: http://doi.org/10.1016/j.vaccine.2010.10.015
- Pereira R.C., Silva A.N., Souza M.C., Silva M.V., Neves P.P., Silva A.A., et al. An inactivated yellow fever 17DD vaccine cultivated in Vero cell culture. Vaccine. 2015; 33(35): 4261-8. DOI: http://doi.org/10.1016/j.vaccine.2015.03.077
- Иванов А.П., Клеблеева Т.Д., Иванова О.Е. Опыт применения IgY-технологии для лабораторной диагностики вирусных инфекций. Вопросы вирусологии. 2020; 65(1): 21-6. DOI: http://doi.org/10.36233/0507-4088-2020-65-1-21-26.
- Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976; 72(1-2): 248-54. DOI: http://doi.org/10.1006/abio.1976.9999
- Ivanov A.P., Bashkirtsev V.N., Tkachenko E.A. Enzyme-linked immunosorbent assay for detection of arenaviruses. Arch. Virol. 1981; 67(1): 71-4. DOI: http://doi.org/10.1007/BF01314603
- Mercier-Delarue S., Durier C., Colin de Verdiere N., Poveda JD., Meiffredy V., Garcia MDF., et al. Screening test for neutralizing antibodies against yellow fever virus, based on flavivirus pseudotype. PLoS One. 2017; 12(5): e0177882. DOI: http://doi.org/10.1371/journal.pone.0177882
- Lindsey N.P., Schroeder B.A., Miller E.R., Braun M.M., Hinkley A.F., Marano N., et al. Adverse event reports following yellow fever vaccination. Vaccine. 2008; 26(48): 6077-82. DOI: http://doi.org/10.1016/j.vaccine.2008.09.009
- Alexander L.N., Seward J.F., Santibanez T.A., Pallansch M.A., Kew O.M., Prevots D.R., et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA. 2004; 292(14): 1696-701. DOI: http://doi.org/10.1001/jama.292.14.1696
